Kodiak Sciences stock saw significant rise over 150% at the opening bell after its drugs achieved success in a key trial. The stock continued to rise, doubling in value as the new eye disease drug matched Eylea in a phase 3 trial. Additional reports indicated the stock gained 172% as Kodiak's drugs targeted Regeneron's Eylea. The company's stock price rose sharply toward $100 following strong phase 3 key trial data for wet AMD.
More Top Stories
The Trump administration's tariffs on Canadian goods are causing concerns in the dairy sector
The Trump administration's tariffs on Canadian goods are causing issues for dairy producers and retailers, wit...
2026 NRL Grand Final tickets are available online
Tickets for the 2026 NRL Grand Final are now available. Tickets for the event can be purchased through NRL.com...
Taylor Townsend's triumph at the US Open 2026
Taylor Townsend shared that her relationship with Serena Williams has evolved. She recently secured a historic...
Brown bears take center stage in Fat Bear Week 2026
Fat Bear Week 2026 has kicked off with sixteen brown bears competing for the championship. Chunk, the defendin...
Victor Radley's new report for hip drop incident
Victor Radley, an player for the Roosters, has been placed on report again. The incident involved a tackle on...
Russell secures victory in Baku
George Russell claimed the top spot in the Azerbaijan Grand Prix, occurring on a Saturday. Max Verstappen fini...
News Roundup · Community Report · Weekly Review · Local Briefing · Community Report · News Roundup · News Roundup · Latest Update · Daily Digest · Local Briefing · Daily Digest · Latest Update · Weekly Review · Daily Digest · Weekly Review · Local Briefing · News Roundup · Latest Update · Latest Update · Daily Digest · Weekly Review · Community Report · Local Briefing · News Roundup · Latest Update · Daily Digest · Weekly Review · Local Briefing · Latest Update · Daily Digest · Weekly Review · Daily Digest · Local Briefing · Local Briefing · Community Report · Weekly Review · Community Report · Latest Update · Latest Update · Daily Digest